Dulaglutide biosimilar (Dongguan Chang An East Light)

度拉糖肽生物类似药（东阳光药）

Report date: 2022/04/24 20:00:23

Base Information

Drug NameDulaglutide biosimilar (Dongguan Chang An East Light)
Drug Alias Name14028注射液
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Biosimilar
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesDongguan Dongguan Sunshine Pharmaceutical Research and Development Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSunshine Lake Pharma Co LtdDongguan City Hec Biological Medicine Res And Development Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A